NovoCure Limited (FRA:038)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Tumor Treating Fields (TTFields)	605.22M	509.34M	537.84M	535.03M	494.37M
Tumor Treating Fields (TTFields) Growth	18.82%	-5.30%	0.53%	8.23%	40.72%
Total	605.22M	509.34M	537.84M	535.03M	494.37M
Total Growth	18.82%	-5.30%	0.53%	8.23%	40.72%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
United States	391.80M	349.74M	406.89M	353.11M	340.78M
United States Growth	12.03%	-14.05%	15.23%	3.62%	46.38%
Germany	65.26M	60.21M	46.12M	93.94M	93.26M
Germany Growth	8.39%	30.55%	-50.90%	0.72%	7.74%
France	55.73M	11.74M	-	-	-
France Growth	374.86%	-	-	-	-
Japan	32.57M	31.67M	32.78M	34.64M	29.08M
Japan Growth	2.85%	-3.40%	-5.37%	19.14%	62.33%
Other International Markets	42.47M	32.76M	30.71M	30.58M	-
Other International Markets Growth	29.65%	6.66%	0.44%	-	-
Greater China	17.39M	23.22M	21.33M	22.77M	12.59M
Greater China Growth	-25.14%	8.87%	-6.29%	80.82%	139.58%
Europe, Middle East and Africa (EMEA) (Excluding Germany)	-	-	-	-	18.65M
Europe, Middle East and Africa (EMEA) (Excluding Germany) Growth	-	-	-	-	112.41%
Total	605.22M	509.34M	537.84M	535.03M	494.37M
Total Growth	18.82%	-5.30%	0.53%	8.23%	40.72%

Source: S&P Global Market Intelligence.